• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    Athersys, Inc. (ATHX)

    2.31 Up 0.06(2.67%) Apr 29, 4:00PM EDT
    ProfileGet Profile for:
    Athersys, Inc.
    3201 Carnegie Avenue
    Cleveland, OH 44115
    United States - Map
    Phone: 216-431-9900
    Fax: 216-361-9495
    Website: http://www.athersys.com

    Index Membership:N/A
    Full Time Employees:57

    Business Summary 

    Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which is in Phase II clinical trials for the treatment of ischemic stroke and inflammatory bowel disease (IBD); and that has completed Phase I clinical trial for the treatment of acute myocardial infarction and hematopoietic stem cell transplant/graft-versus-host disease. It is also developing MultiStem cell therapy for the treatment of acute respiratory distress syndrome. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. In addition, the company is involved in identifying and developing small molecule compounds with potential applications in indications, including obesity; related metabolic conditions, such as diabetes; and neurological indications consisting of schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat IBD; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; and collaboration with Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets produced compound screening and development. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Athersys, Inc.

    Key Executives 
    Dr. Gil Van Bokkelen Ph.D., 55
    Co-Founder, Chairman and Chief Exec. Officer
    Mr. William B. J. Lehmann Jr., J.D., MBA, 50
    Pres and Chief Operating Officer
    Dr. John J. Harrington Ph.D., 49
    Co-Founder, Chief Scientific Officer, Exec. VP and Director
    Ms. Laura K. Campbell CPA, 52
    Sr. VP of Fin.
    Dr. Manal Morsy M.D., PH.D.,
    VP of Global Regulatory Affairs
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders